Therefore, targeting the tumor suppressor p53 and its negative regulator MDM2/MDMX to activate p53 in vitro and in vivo provides a feasible therapeutic strategy for cancer therapy (Soares et al., 2017; Niu et al., 2018). Here, TP53 is linked to cancer.